Source: International Congress 2017 – Current challenges in COPD evaluation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Bafadhel (Oxford, United Kingdom). Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis. 394

Member's Comments

No comment yet.

Related content which might interest you: Sputum neutrophil elastase and inhaled antibiotic response in bronchiectasis: a post-hoc analysis of the ORBIT-4 trial Source: Virtual Congress 2021 – Bronchiectasis heterogeneity: assessing the endotypes Year: 2021 Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD? Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 The relationship between blood neutrophils, blood eosinophils and exacerbations of COPD – Results from the TIE-study Source: International Congress 2016 – Systemic biomarkers Year: 2016 Cytogenetic analysis in peripheral blood lymphocytes from asthmatic  patients with different severity Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 Proteomic analysis of T-lymphocytes in patients with bronchial asthma Source: Eur Respir J 2006; 28: Suppl. 50, 550s Year: 2006 Comparison of blood and sputum analysis in evaluation of eosinophilic COPD Source: International Congress 2019 – Airway diseases and blood cells Year: 2019 Low versus high Th2 asthma: variability of blood eosinophil counts in a longitudinal analysis Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study Source: ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018 Year: 2019 Correlation of biological markers of inflammation in peripheral blood with bronchoprovocative testing with histamine in patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 287s Year: 2004 The trend of pulmonary function tests over time in COPD patients with different levels of blood eosinophils Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Clinical analysis of acute exacerbation of COPD cases with increased eosinophilic granulocytes in peripheral blood Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis Source: Eur Respir J 2014; 44: 789-791 Year: 2014 Flow cytometric assessment of sputum lymphocyte cytokine profiles in patients with asthma and COPD Source: Eur Respir J 2001; 18: Suppl. 33, 316s Year: 2001 Analysis of cytogenetic alterations in peripheral blood lymphocytes from asthmatic patients treated with oral corticosteroids Source: International Congress 2019 – Identification of new targets and therapeutic strategies for lung disease Year: 2019 Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017 LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): An across-trials model-based approach Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020 Effect of extrafine medium strength (MS) ICS-containing triple therapy on exacerbations in asthmatics with persistent airflow limitation: A post-hoc analysis of the TRIMARAN study Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016